Étiquette : pharmacologie

An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies, Kerstin IFFLAND, Franjo GROTENHERMEN, 2017

An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies Kerstin IFFLAND, Franjo GROTENHERMEN Cannabis and Cannabinoid Research, 2017, 2, (1), 139–154. DOI: 10.1089/can.2016.0034 https://www.liebertpub.com/doi/10.1089/can.2016.0034?utm_source=sfmc&utm_medium=email&utm_campaign=CAN%20OA%20Feb%201%202019&d=2/1/2019&mcid=1909944349   Abstract Introduction: This literature survey aims to extend the comprehensive survey performed by Bergamaschi et al. in 2011 on cannabidiol (CBD) safety and side effects. Apart from updating the literature, this article focuses on clinical studies and CBD potential interactions with other drugs. Results: In general, the often described favorable safety profile of CBD in humans was confirmed and extended by the reviewed research. The majority of studies were performed for treatment of epilepsy [...]

Lire la suite

Marijuana, National Institute on Drug Abuse (NIDA), June 2018

Marijuana, National Institute on Drug Abuse (NIDA), June 2018 Table of Contents Marijuana Letter From the Director What is marijuana? What is the scope of marijuana use in the United States? What are marijuana effects? How does marijuana produce its effects? Does marijuana use affect driving? Is marijuana addictive? What are marijuana's long-term effects on the brain? Is marijuana a gateway drug? How does marijuana use affect school, work, and social life? Is there a link between marijuana use and psychiatric disorders? What are marijuana's effects on lung health? What are marijuana’s effects on other aspects of physical health? Is marijuana safe and effective as medicine? What are the effects of secondhand exposure to marijuana smoke? Can marijuana [...]

Lire la suite

Medicinal cannabis : History, Pharmacology and Implication for the Acute Care Settings, M. Barna Bridgeman, D.T. Abazia, Pharmacy & Therapeutics, 2017, 42, 3,180-188.

Medicinal cannabis : History, Pharmacology and Implication for the Acute Care Settings Mary Barna Bridgeman, PharmD, BCPS, BCGP; and Daniel T. Abazia, PharmD, BCPS, CPE Pharmacy & Therapeutics®, 2017 • Vol. 42 No. 3, pp 180-188.   INTRODUCTION Medicinal cannabis, or medicinal marijuana, is a therapy that has garnered much national attention in recent years. Controversies surrounding legal, ethical, and societal implications associated with use; safe administration, packaging, and dispensing; adverse health consequences and deaths attributed to marijuana intoxication; and therapeutic indications based on limited clinical data represent some of the complexities associated with this treatment. Marijuana is currently recognized by the U.S. Drug Enforcement Agency’s [...]

Lire la suite

Medicinal cannabis – Potential Drug Interactions, M.A. Alsherbiny, C. Guang Li, décembre 2018

Medicinal cannabis - Potential Drug Interactions M.A. Alsherbiny, C. Guang Li, décembre 2018. www.preprints.org,  doi:10.20944/preprints201812.0032.v1   https://www.researchgate.net/publication/329559938_Medicinal_Cannabis_-_Potential_Drug_Interactions   Endocannabinoids system (ECS) engrossed a considerable interest as potential therapeutic targets in various carcinomas and cancer related conditions alongside with neurodegenerative diseases. Cannabinoids are implemented in several physiological processes such as appetite stimulation, energy balance, pain modulation and the control of chemotherapy induced nausea and vomiting (CINV). However, pharmacokinetics and pharmacodynamics interactions could be perceived in drug combinations, so in this short review we tried to shed the light over the potential drug interactions of medicinal cannabis. Hitherto, few data have been provided to the healthcare practitioners about [...]

Lire la suite

Cannabis and the Anxiety of Fragmentation – A Systems Approach for Finding an Anxiolytic Cannabis Chemotype, B. S. Kamal et al., 2018

Cannabis and the Anxiety of Fragmentation - A Systems Approach for Finding an Anxiolytic Cannabis Chemotype, B. S. Kamal, F. Kamal, D. E. Lantela, Frontiers in Neuroscience, 2018, 12, article 730. https://doi.org/10.3389/fnins.2018.00730   Abstract : Cannabis sativa is a medicinal herb with a diverse range of chemotypes that can exert both anxiolytic and anxiogenic effects on humans. Medical cannabis patients receiving organically grown cannabis from a single source were surveyed about the effectiveness of cannabis for treating anxiety. Patients rated cannabis as highly effective overall for treating anxiety with an average score of 8.03 on a Likert scale of 0 to 10 (0 = not effective, [...]

Lire la suite

The endocannabinoid system as a target for novel anxiolytic drugs, S. Patel et al., 2017

The endocannabinoid system as a target for novel anxiolytic drugs S. Patel, M.N. Hill, J.F. Cheer, C.T. Wotjak, A. Holmes, Neuroscience and Biobehavioral Reviews, 2017, 76, 56-66. https://doi.org/10.1016/j.neubiorev.2016.12.033 Abstract The endocannabinoid (eCB) system has attracted attention for its role in various behavioral and brain functions, and as a therapeutic target in neuropsychiatric disease states, including anxiety disorders and other conditions resulting from dysfunctional responses to stress. In this mini-review, we highlight components of the eCB system that offer potential ‘druggable’ targets for new anxiolytic medications, emphasizing some of the less well-discussed options. We discuss how selectively amplifying eCBs recruitment by interfering with eCB-degradation, via fatty [...]

Lire la suite

The Health Effects of Cannabis and Cannabinoids. The Current State of Evidence and Recommendations for Research. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division

https://www.ncbi.nlm.nih.gov/books/NBK425767/   The Health Effects of Cannabis and Cannabinoids The Current State of Evidence and Recommendations for Research National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. Washington (DC): National Academies Press (US); 2017 Jan 12. ISBN-13: 978-0-309-45304-2ISBN-10: 0-309-45304-6 Copyright and Permissions Hardcopy Version at National Academies Press Significant changes have taken place in the policy landscape surrounding cannabis legalization, production, and use. During the past 20 years, 25 states and the District of Columbia have legalized cannabis and/or cannabidiol (a component of cannabis) for [...]

Lire la suite

Contribution à une exploration des propriétés thérapeutiques de cannabis, F-R. Ingold, C. Sueur, C. Kaplan, Annales Médico-Psychologiques, 2015, 173, 453-459

https://www.researchgate.net/publication/275672267_Contribution_a_une_exploration_des_proprietes_therapeutiques_du_cannabis Contribution à une exploration des propriétés thérapeutiques du cannabis F. R. INGOLD ; C. SUEUR ; C. D. KAPLAN | Dans Annales Médico-Psychologiques, Revue psychiatrique (Vol.173, n°5, Juin 2015) Résumé Nous rendons ici hommage à Moreau (de Tours) pour son travail sur le haschisch et les essais thérapeutiques avant-gardistes qu’il a menés. Le cannabis est connu pour ses utilisations à visée thérapeutique depuis au moins 6000ans avant notre ère. Nous examinons les données ethnobotaniques, biologiques et cliniques qui font état de ces usages. L’identification récente des premiers cannabinoïdes et de leurs mécanismes d’action via les récepteurs CB1 et CB2 a été à [...]

Lire la suite

Le Cannabis (marihuana, marijuana) et les cannabinoïdes. Renseignements destinés aux professionnels de la Santé, Santé Canada, octobre 2018

https://www.canada.ca/fr/sante-canada/services/drogues-medicaments/cannabis/renseignements-medecins/renseignements-destines-professionnels-sante-cannabis-cannabinoides.html   Renseignements destinés aux professionnels de la santé : Le cannabis (marijuana, marihuana) et les cannabinoïdes (Version PDF - 2,690 Ko) Plante séchée ou fraîche et huile destinées à l'administration par ingestion ou par d'autres moyens Agent psychoactif Le présent document a été préparé par la Direction générale de la légalisation et réglementation du cannabis de Santé Canada pour fournir des renseignements sur l'usage du cannabis (marihuana) et des cannabinoïdes à des fins médicales. Le présent document est un résumé d'articles scientifiques examinés par les pairs et de revues internationales sur les utilisations thérapeutiques possibles et sur les effets néfastes du cannabis et des [...]

Lire la suite

Le Cannabis en Médecine (Neurologie et Psychiatrie) – Revue de la Littérature

Dr Christian SUEUR Psychiatre, praticien hospitalier GRECC (Groupe de Recherches et d’Etudes Clinique sur les Cannabinoïdes) Lyon/Bron, christian.sueur@ch-le-vinatier.fr   Dr François Rodolphe INGOLD Psychiatre, anthropologue GRECC, Paris         Le développement de l’utilisation thérapeutique du cannabis, et des cannabinoïdes naturels, ou de synthèse, connaît depuis quelques années un accroissement exponentiel impressionnant, dans tous les pays ou les lois ont été modifiées dans le sens de permettre l’utilisation thérapeutique de ce « stupéfiant », le delta-9-THC contenu dans le cannabis (Cannabis Indica et Cannabis Sativa) et tous les dérivés de la marijuana. L’autre cannabinoïde présentant d’incontestables propriétés thérapeutiques, le cannabidiol, n’est pas, lui, considéré comme stupéfiant, et son utilisation ne rencontre pas les mêmes [...]

Lire la suite